BA.4/BA.5 early surge report Austria

- 3 Alexander Gamisch^a, Maria Elisabeth Mustafa^a
- 5 ^aDr. Mustafa, Dr. Richter Labor für medizinisch-chemische und mikrobiologische Diagnostik
- 6 GmbH, Abteilung Molekularbiologie, Strubergasse 20, 5020 Salzburg
 - Abstract

1 2

4

7

8

- 9 More than two years into the COVID-19 pandemic, the emergence of the Omicron subvariants
- BA.4 and BA.5 initiated the fifth wave. BA.4/BA.5 share identical spike proteins and are thus
- difficult to differentiate using standard diagnostic tests. The true frequency and diversity of the
- 12 two variants in Austria is therefore largely unknown. Aim of this report is to take stock about
- the frequency and diversity of BA.4 & BA.5 and their subvariants based on whole genome
- sequencing (WGS) data as deposited at GISAID database. Results show that most sequenced
- cases belong to BA.5 (c. 86 %) rather than BA.4 (c. 14 %) and that most of the global diversity
- 16 (24 out of 32 subvariants) of BA.4 and BA.5 in terms of subvariants described is already present
- in Austria. However, most cases can be attributed to a few subvariants (e.g. BA.5.1, BE.1.1,
- 18 BA.5.3, BA.5.2.1) with high estimated growth advantage over BA.2 (ranging 103 to 159 %)
- and may be worth monitoring as the immediate wave unfolds.

Introduction

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

At the dawn of 2022, more than two years into the COVID-19 pandemic, the emergence of the Omicron subvariants BA.4 and BA.5 in South Africa initiated the fifth wave (Tegally et al. 2022, Mohapatra et al. 2022). In Austria BA.4/BA.5 was first detected mid-May (calendar week 15) and became dominant within weeks in combination with rising cases numbers (AGES¹) thereby dampen any hope for a "summer break" before autumn. BA.4/BA.5 carry additional spike mutations (69-70del, L452R, F486V and the wild type amino acid at Q493) than BA.2 and are likely more transmissible than the latter due to immune evasion (Tegally et al. 2022; Hoteit and Yassine 2022; Hachmann et al. 2022). BA.4/BA.5 are further hardly distinguishable by PCR based screening tests and partial genome sequencing approaches that commonly target the spike gene region (cf. O'Toole et al. 2022; ECDC 2022). As a corollary, the true frequency and diversity of the two variants in Austria is largely unknown. Moreover, at the time of writing 32 more obscure subvariants of BA.4 and BA.5 have already been described². These subvariants usually represent epidemiological significant clusters with a significant amount of onward transmission that are defined by at least one unambiguous evolutionary event (viz. mutation; Rambaut et al. 2020). Most mutations are inconsequential, but some do alter the biological properties of the virus (e.g. Saito et al. 2022; Tegally et al. 2022; Hoteit and Yassine 2022; Hachmann et al. 2022). Therefore, it is useful to track the frequency of the mutations/subvariants when they emerge. Aim of this report is to provide an overview about the frequency and diversity of BA.4 & BA.5 and their subvariants in Austria based on public available whole genome sequencing (WGS) data as deposited at GISAID database (Elbe & Buckland-Merrett 2017). The potential risk of these subvariants in terms of relative growth advantage versus a BA.2 baseline is assessed.

Methods

A total of 1199 complete genomes of BA.4 and BA.5 collected in Austria have been downloaded from GISAID (Elbe & Buckland-Merrett 2017; GISAID accessed on 08.07.22). Sequences have then been classified to the Pango-nomenclatur system (Rambaut et al. 2020) using the Nextclade online tool³ v.2.0.0 (Aksamentov et al. 2021) and the frequencies per variant over sampling time were recorded. The Nextclade mutation profile was further used to manually designate novel variants⁴ not yet recognized by the software. Finally, the

¹ https://www.ages.at/mensch/krankheit/krankheitserreger-von-a-bis-z/coronavirus#c12422 [accessed 04.07.22]

 $^{^2 \ \}underline{\text{https://github.com/cov-lineages/pango-designation}} \ [accessed \ 04.07.22]$

³ https://clades.nextstrain.org [accessed 08.07.22]

⁴ https://www.pango.network/summary-of-designated-omicron-lineages/ [accessed 04.07.22]

52 Covspectrum⁵ (Chen et al. 2022) platform was used to query GISAID genomic data for global

variant frequencies and to calculated transmission advantage versus a BA.2 baseline following

Chen et al. (2021). Due to the limited number of Austrian BA.4/BA.5 genomes (n =1199; see

also Tab.1) the relative growth advantage per week (in percentage; 0% means equal growth) in

the timeframe of the last 3 months [2022-04-04 to 2022-07-04] was calculated based on

57 European genomes.

53

54

55

56

58

59

60

63

64

65

66

67

68

69

70

72

73

74

75

76

77

79

80

81

82

83

84

Results and Discussion

BA.4 versus BA.5

All BA.4 and BA.5 subvariants exhibit strong relative growth advantage versus BA.2 (ranging

between 21% and 175%; see Tab. 1) on a continental scale. For comparison, the Alpha variant

(B.1.1.7) exhibit a growth advantage of 43–52 % compared to the "Wild type" SARS-CoV 2

strain (Chen et al. 2021). However, growth advantage of BA.4 subvariants is tendentially lower

than those of BA.5 subvariants (Tab.1). Consequently, albeit BA.4 initially was more frequent

in Austria than BA.5 the proportion has shifted in favor of BA.5 in recent weeks (around

calendar week 17) (Fig.1). Now, in concordance with the global trend, the BA.5 variant is

dominant with c. 86 % (1035/1199) compared to BA.4 (c. 14 % (164/1199) in Austria (Fig.1).

BA.4/BA5 subvariants

From the 32 subvariants of BA.4/BA5 a total of 24 subvariants were already detected in Austria

over the past 12 weeks (calendar week 15 to 26) (Fig.1, Fig.2) likely due to multiple

independent introductions of the different strains. In Austria, the top five most frequently

sequenced subvariants over the whole timeframe are BA.5.1, BE.1.1, BA.5.3, BA.5.2.1 and

BA.5 thereby representing a total of c. 68 % of cumulative cases sequenced. Of those BA.5.1,

BE.1.1 and BA.5.2.1 show signs of sustained growth whereas BA.5.3 apparently peaked in

calendar week 19 and is on decline ever since. The top five subvariants with the highest growth

78 advantage (ranging between 175 and 151 %) are BA.5.1.2, BE.1, BE.1.1, BA.5.6, BA.5.2.3

whereas three of those (BA.5.6, BA.5.2.3, BA.5.1.2) are only known from a handful of recent

cases in Austria so far (Tab.1, Fig. 3). The variants BE.1.1, BA.5.2.1, BA.5.1 on the other hand

appear to be more successful than their peers when judged by cases numbers and estimated

growth advantages (Tab.1, Fig. 3) and may be worth monitoring as the proximate wave unfolds.

⁵ https://cov-spectrum.org [accessed 04.07.22]

Acknowlegements

We gratefully acknowledge all data contributors, i.e. the authors and their originating laboratories responsible for obtaining the specimens, and their submitting laboratories for generating the genetic sequence and metadata and sharing via GISAID. Following labs submitted to GISAID: Bergthaler laboratory, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Lifebrain Covid Labor GmbH; Dr. Mustafa, Dr. Richter Labor für medizinisch-chemische und mikrobiologische Diagnostik GmbH, Abteilung Molekularbiologie; Center for Virology, Medical University of Vienna; Institute of Virology Department of Hygiene, Microbiology and Public Health at Innsbruck Medical University.

References

99

103

107

111

114

118

122

125

- Aksamentov, I., Roemer, C., Hodcroft, E. B., & Neher, R. A. (2021). Nextclade: clade
- assignment, mutation calling and quality control for viral genomes. *Journal of Open Source*
- 102 Software, 6(67), 3773.
- 104 Chen, C., Nadeau, S. A., Topolsky, I., Manceau, M., Huisman, J. S., Jablonski, K. P., ... &
- Stadler, T. (2021). Quantification of the spread of SARS-CoV-2 variant B. 1.1. 7 in
- 106 Switzerland. Epidemics, 37, 100480.
- 108 Chen, C., Nadeau, S., Yared, M., Voinov, P., Xie, N., Roemer, C., & Stadler, T. (2022). CoV-
- 109 Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new
- 110 variants. *Bioinformatics*, 38(6), 1735-1737.
- Elbe, S., & Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's innovative
- 113 contribution to global health. *Global challenges*, 1(1), 33-46.
- European Centre for Disease Prevention and Control (ECDC). Implications of the emergence
- and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA 14
- 117 June 2022. ECDC: Stockholm; 2022.
- Hachmann, N. P., Miller, J., Collier, A. R. Y., Ventura, J. D., Yu, J., Rowe, M., ... & Barouch,
- D. H. (2022). Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12. 1, BA.
- 4, and BA. 5. New England Journal of Medicine. 387, 86-88.
- Hoteit, R., & Yassine, H. M. (2022). Biological Properties of SARS-CoV-2 Variants:
- Epidemiological Impact and Clinical Consequences. *Vaccines*, *10*(6), 919.
- Mohapatra, R. K., Kandi, V., Sarangi, A. K., Verma, S., Tuli, H. S., Chakraborty, S., ... &
- Dhama, K. (2022). The recently emerged BA. 4 and BA. 5 lineages of Omicron and their
- global health concerns amid the ongoing wave of COVID-19 pandemic–Correspondence.
- 129 International Journal of Surgery (London, England), 103, 106698.

- O'Toole, Á., Pybus, O. G., Abram, M. E., Kelly, E. J., & Rambaut, A. (2022). Pango lineage
- designation and assignment using SARS-CoV-2 spike gene nucleotide sequences. BMC
- 133 *genomics*, 23(1), 1-13.

134

138

142

146

- Rambaut, A., Holmes, E. C., O'Toole, Á., Hill, V., McCrone, J. T., Ruis, C., ... & Pybus, O.
- G. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
- epidemiology. *Nature microbiology*, 5(11), 1403-1407.
- 139 Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., ... & de
- Oliveira, T. (2022). Continued emergence and evolution of Omicron in South Africa: New
- 141 BA. 4 and BA. 5 lineages. *medRxiv*.
- 143 Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., ... & Sato, K. (2022).
- Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. *Nature*,
- 145 602(7896), 300-306.



148 Figures




Figure 1. Omicron subvariants BA.4 and BA.5 genomes over time (calendar weeks) in Austria. A, BA.4 and BA.5 including subvariants over time. B, subvariants of BA.4 and BA.5 over time.

Figure 2. Heatmap of number BA.4 and BA.5 genomes over time (between calendar

week 15 and 26) in Austria

156

157

	calendar week											
	15	16	17	18	19	20	21	22	23	24	25	26
BA.4	0	2	0	2	1	7	2	2	4	16	10	10
BA.4.1	0	0	0	1	1	8	6	0	3	11	5	6
BA.4.1.1	0	0	0	4	3	4	4	0	2	1	0	0
BA.4.1.2	0	12	3	3	0	14	4	1	0	2	1	1
BA.4.2	0	0	0	0	0	0	0	0	0	1	0	0
BA.4.4	1	1	1	0	0	1	0	1	1	0	1	0
BA.5	0	0	0	1	1	0	1	0	44	11	4	16
BA.5.1	0	0	1	2	5	26	48	11	50	68	60	86
BA.5.1.2	0	0	0	0	0	0	0	0	1	0	2	0
BA.5.1.3	0	0	0	0	0	2	2	0	1	1	3	4
BA.5.2	0	0	0	0	0	3	0	1	7	20	21	26
BA.5.2.1	0	0	0	2	0	6	5	2	1	24	28	38
BA.5.2.3	0	0	0	0	0	0	0	0	0	1	1	0
BA.5.3	0	2	2	24	30	19	20	2	7	2	3	1
BA.5.3.1	0	0	0	0	0	1	0	0	0	3	1	1
BA.5.3.2	0	0	1	1	0	1	5	0	0	2	0	1
BA.5.3.3	0	0	0	0	0	0	0	0	0	1	0	1
BA.5.3.4	0	0	0	0	0	0	0	0	0	0	1	0
BA.5.5	0	0	0	0	0	0	1	1	1	2	2	5
BA.5.6	0	0	0	0	0	0	0	1	0	1	0	3
BE.1	0	0	0	3	2	8	8	0	5	8	7	14
BE.1.1	0	0	2	1	0	0	8	1	15	53	46	37
BF.1	0	0	0	0	1	5	2	0	1	8	2	10
BF.3	0	0	0	0	0	0	0	0	0	2	0	0




Figure 3. Subvariant growth advantage vs. BA.2 and genomes number



Tables
Table 1. BA.4 and BA.5 subvariants, frequency, associated mutations, genome frequency global and in Austria as well as growth advantage
versus BA.2 based on genomic sequencing data.

Subvariant	Initial predominant countries ^a	Associated mutation(s) ^a	Globalb	Austria	Current adv. per week (%) ^b	Conf. int. (%) ^b
BA.4	South Africa	parental lineage	26452*	164*	93%	91-95%
BA.4.1	South Africa	T21570G (S:V3G)	16194*	41	84%	82-87%
BA.4.1.1	South Africa and Germany	A23570G (S:I670V)	938	18	76%	69-83%
BA.4.1.2	Austria	C3176T (Orf1a:P971S)	168	41	21%	14-27%
BA.4.1.3	Israel	A2435G (Orf1a:R724G)	122	0	NA	NA
BA.4.1.4	Israel	G25266T (S:C1235F)	320	0	NA	NA
BA.4.2	USA	C5173A (Orf1a:H1636Q)	767	1	107%	84-130%
BA.4.3	Israel	C21365T (Orf1b:P2633L)	169	0	72%	37-106%
BA.4.4	USA	C25708T (Orf3a:L106F)	1491	7	101%	92-111%
BA.4.5	Australia	G22104A (S:G181E)	154	0	NA	NA
BA.5	South Africa	parental lineage	65951*	1035*	112%	111-114%
BA.5.1	Portugal	C29666T (ORF10:L37F)	23037*	357	103%	102-105%
BA.5.1.1	USA	C25672A (Orf3a:L94I)	806	0	NA	NA
BA.5.1.2	Europe	G27214A (Orf6:V5I)	270	3	151%	131-172%
BA.5.1.3	Germany Portugal and Spain	G22427A (S:V289I)	709	13	114%	105-122%
BA.5.2	South Africa, England and USA	A28330G (ORF9b:D16G)	21221*	78	133%	130-136%
BA.5.2.1	South Africa, England and USA	A27038G (ORF5:T172T)	12918	106	125%	122-128%
BA.5.2.2	France, Martinique	G20356A (Orf1b:G2297S)	257	0	85%	74-96%
BA.5.2.3	UK	G625T (Orf1a:K120N)	334	2	175%	154-196%
BF.1	England, Denmark, Spain and Scotland	G21520T (Orf1ab:V7086F) (Orf1b:2685F)	1944*	0	90%	85-94%
BF.1.1	USA	G10835A (Orf1a:V3524I)	191	29	75%	41-109%
BF.2	Denmark	G14398T (Orf1b:V311L)	260	2	122%	106-137%
BF.3	India	C23202T (S:T547I)	137	0	NA	NA
BF.4	England	A22337G (S:T259A)	248	0	134%	115-153%
BA.5.3	Germany and South Africa	C1931A (ORF1ab:Q556K)	10338*	112	105%	103-108%



BA.5.3.1	South Africa, Austria and England	G28681T (N:E136D)	1933	6	150%	145-154%
BA.5.3.2	Germany	G621A (ORF1ab:R119H)	784	11	67%	62-71%
BA.5.3.3	UK	C6843T (Orf1a:S2193F)	369	2	118%	105-130%
BA.5.3.4	Germany	G20718T (Orf1b:M2417I)	267	1	64%	56-71%
BE.1	South Africa, Austria and England	G16935A (ORF1b:M1156I)	7321*	55	154%	149-159%
BE.1.1	Germany	C11750T (Orf1a:L3829F)	3817	163	159%	153-165%
BE.2	Belgium	C2910T (Orf1a:T882I)	110	0	66%	53-80%
BA.5.5	USA	C21789T (S:T76I)	6417	12	142%	127-157%
BA.5.6	USA	C17402T (Orf1b:A1312V)	1831	5	169%	144-194%

ahttps://www.pango.network/summary-of-designated-omicron-lineages/ [accessed 04.07.22]

bhttps://cov-spectrum.org [accessed 04.07.22]

*including subvariants